Compare GWAV & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWAV | GRI |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 4.5M |
| IPO Year | 2014 | 2020 |
| Metric | GWAV | GRI |
|---|---|---|
| Price | $2.52 | $2.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | 48.1K | ★ 529.4K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,098,036.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 116184.26 | N/A |
| 52 Week Low | $2.19 | $0.18 |
| 52 Week High | $24.00 | $6.70 |
| Indicator | GWAV | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 36.69 | 51.86 |
| Support Level | N/A | $1.71 |
| Resistance Level | $3.93 | $2.58 |
| Average True Range (ATR) | 0.60 | 0.22 |
| MACD | -0.18 | -0.00 |
| Stochastic Oscillator | 4.91 | 29.47 |
Greenwave Technology Solutions Inc through its subsidiary, is an operator of several metal recycling facilities in Virginia, Ohio, & North Carolina. At these facilities, the company collects, classifies, & processes appliances, construction materials, end-of-life vehicles, boats, & industrial machinery. The company processes these items by crushing, shearing, shredding, separating, & sorting into smaller pieces & categorizes these recycled ferrous, nonferrous, & mixed metal pieces based on density & metal type before sale. For scrap cars, it removes the catalytic converters, aluminum wheels, & batteries for separate processing & sale before shredding the vehicle. The company is organized into three operating segments: Scrap Metal Recycling, Hauling, & Other (comprised of rental income).
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.